Advertisement

Topics

Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association

09:48 EDT 17 May 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that data from the Company’s oral, small molecule, complement C5 inhibitor program and data from the Company’s global, Phase 2 clinical program evaluating RA101495 SC fo...

Other Sources for this Article

Investors:
Ra Pharmaceuticals, Inc.
Jennifer Robinson, 617-674-9873
jrobinson@rapharma.com
or
Media:
Argot Partners
David Rosen, 212-600-1902
david.rosen@argotpartners.com

NEXT ARTICLE

More From BioPortfolio on "Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...